Concerns continue to exist in using thrombolytics for patients with PE. This trial enrolled patients with symptomatic moderate PE (>70% involvement of at least 2 lobes, or 1 main pulmonary artery). TPA was given as a 10mg bolus, then 40mg over 2 hours (or 0.5mg/kg for those <50kg). After ~2 years, pulmonary HTN was present in 16% of the thrombolytic group and 57% of the control group, mean hospital stay was shorter (2.2 vs 4.9 days), and there were no differences between the groups in mortality or bleeding (abstract).
Share This Post
Categories
Related Posts
While spring 2020 feels like a lifetime ago, COVID-19 is still with us. Unfortunately, this winter has brought more infections, hospitalizations, and death rates that eclipse what many saw last spring. But this time, while the headlines are back about hospitals running low on PPE, ICU bed shortages, and long lines for testing, we now […]
This article is part of a series in The Hospital Leader written by members of the Division of Hospital Medicine at Dell Medical School at The University of Texas in Austin, exploring lessons learned from the coronavirus pandemic and outlining an approach for creating COVID-19 Centers of Excellence. Evidence on emerging treatments for COVID-19 has […]
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Leave A Comment